ICH Q11 – Definisjon av startmaterialer – Fleksibilitet og dokumentasjonskrav Andreas Sundgren LMI 17. april 2012.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

Dr. Birgit Schmauser, BfArM, Bonn
Integrating the gender aspects in research and promoting the participation of women in Life Sciences, Genomics and Biotechnology for Health.
ISO 9001:2000 Documentation Requirements
Transition from Q1- 8th to Q1- 9th edition
Annual Product Review (APR) Product Quality Review (PQR)
Finished Pharmaceutical Product Specifications
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
ISO 9001 : 2000.
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
Batch Reworking and Reprocessing
World Health Organization
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
World Health Organization
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
Determine impurity level in relevant batches1
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Reference, Retention and Reserve Samples
Prepared by Long Island Quality Associates, Inc. ISO 9001:2000 Documentation Requirements Based on ISO/TC 176/SC 2 March 2001.
QUALITY CONTROL OF PHYSICO-Chemical METHODS Introduction :Validation توثيق المصدوقية.
Codex Guidelines for the Application of HACCP
Power Extraction Research Using a Full Fusion Nuclear Environment G. L. Yoder, Jr. Y. K. M. Peng Oak Ridge National Laboratory Oak Ridge, TN Presentation.
Introduction to ISO New and modified requirements.
Chapter 8: Problem Solving
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
1 Framework Programme 7 Guide for Applicants
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
The following minimum specified ranges should be considered: Drug substance or a finished (drug) product 80 to 120 % of the test concentration Content.
ISO 9001:2000 QUALITY MANAGEMENT SYSTEM REQUIREMENTS
PQRI Work Project Concept Fundamental Understanding of Sulfonate Ester-Forming Reactions April 2006.
Guidance on Establishing Monitoring to Comply with CAM and Other Title V Requirements A Summary of Technical and Policy Materials Barrett Parker, EPA,
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Product Documentation Chapter 5. Required Medical Device Documentation  Business proposal  Product specification  Design specification  Software.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
ISO 9001:2008 to ISO 9001:2015 Summary of Changes
Lecture 7: Requirements Engineering
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
BioTx Pharmaceutical Sciences Movement within the design space with a robust control strategy Jon Coffman, Ph.D. Principal Engineer III BioTherapeutic.
Overview of FDA's Regulatory Framework for PET Drugs
Molecule-to-Market-Place Quality
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Validation | Slide 1 of 27 August 2006 Validation Supplementary Training Modules on Good Manufacturing Practice WHO Technical Report Series, No. 937, 2006.
ISO 9001:2000 The 5 Phase Plan to Implementation Sterling, VA Terry & Associates Quality.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
The common structure and ISO 9001:2015 additions
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Impurities in Drugs author: srikanth N
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
In the name of God. Common Technical Document On Biotech.
EIAScreening6(Gajaseni, 2007)1 II. Scoping. EIAScreening6(Gajaseni, 2007)2 Scoping Definition: is a process of interaction between the interested public,
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Dr Pascale POUKENS-RENWART Scientific Officer
Author: Nurul Azyyati Sabri
Dr. Birgit Schmauser, BfArM, Bonn
WHO Technical Report Series, No. 953, 2009
Quality Risk Management
PQRI Project Update Fundamental Understanding of Sulfonate Ester-Forming Reactions Date of Original Submission: April 2006 Date of Current Report: February.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Quality by Design.
World Health Organization
Quality guidelines on impurities
Radiopharmaceutical Production
Quality guidelines on impurities
GL 51 – Statistical evaluation of stability data
GL8 (R) – Stability testing for medicated premixes
Guideline for Elemental Impurities ICH Q3D(R)
Presentation transcript:

ICH Q11 – Definisjon av startmaterialer – Fleksibilitet og dokumentasjonskrav Andreas Sundgren LMI 17. april 2012

Definition of Starting Materials Non-scientific approach: Justification based on complexity/non-complexity of starting materials. Justification based on commercial availability Focus on number of steps, less focus on the manufacturing process as a whole.

Definition of Starting Materials Q11 – A scientific approach: A starting material should be a substance of defined chemical properties and structure. Steps that impact the impurity profile of the drug substance should normally be included in the manufacturing process Changes in material attributes or operating conditions that occur near the beginning of the manufacturing process have lower potential to impact the quality.

Starting Material Active Substance No GMP requirements No detailed description MA holder might have limited access to documentation Limited change control GMP requirements Detailed documentation MA holder has access to relevant documentation Full change control

Definition of Starting Materials Starting Material Manufacturer Starting material Active substance Starting Material Supplier Starting Material Manufacturer Intermediate Starting Material Manufacturer Errors in communication Not same defined SM Different quality control standards Considers their processes confidential

Definition of Starting Materials Formation of stereochemical center All significant impurities from Step 4-6 A or D as Starting Material?

Definition of Starting Materials D acceptable as Starting Material provided that: D can be fully identified from tests in the Starting Material specifications. Full control of all potential stereoisomers.

Definition of Starting Materials Indicates that A should be defined as Starting Material Stereochemistry controlled by the manufacturing process A or D as Starting Material? E, F etc Identity not fully controlled by Specifications

Definition of Starting Materials Second example: Proposed SM Concerns regarding (genotoxic) impurities in Step 4 Indicates that the proposed SM (E) should be redefined to D

Definition of Starting Materials Proposed SM Impurities from the manufacture of D should be insignificant. All significant impurities from Step 4-6 Information on the manufacturing process for D important?

Definition of Starting Materials Commercial availability: Commodity in a pre-existing, non-pharmaceutical market Chemicals produced by custom synthesis are not considered to be commercially available If a justification is needed, it is most likely not commercially available

Definition of Starting Materials Commercial availability: A compound that, based on the manufacturing process, is more expensive to produce by an in-house manufacturing process than to buy from a manufacturer using a “specialised” manufacturing process. Typically manufactured by well established processes

Definition of Starting Materials Examples: Purification Starting MaterialActive Substance ”?” One step Insufficient control of impurities Stereochemistry based on SM man. process

Definition of Starting Materials Examples: Typical daily dose is 3  g SM Latanoprost Necessity to include a large part of the manufacturing process within GMP?

Definition of Starting Materials Examples: BenzydamineSM

Definition of Starting Materials Examples: N-nitrosoamine genotoxic? Benzydamine SM Indicates that the N-nitrosoamine and control of related impurities should be included in the manufacturing process. N-nitrosoamine

Design Space & Documentation Requirements Chapter 6, 7 & 8 in ICH Q11 Should be read in conjuction with Q8, Q9 & Q10 Guidelines discusses approach, not requirements. Presentation by the ICH Quality Implementation Working Group:

Design Space & Documentation Requirements What is a design space? ”…the multidimensional combination and interaction of input varables and process parameters that have been demonstrated to provide assurance of quality.””…the multidimensional combination and interaction of input varables and process parameters that have been demonstrated to provide assurance of quality.” Working within a design space is not considered as a change. The Guidelines applicable also to one or two dimensions, e.g. flexibility for one parameter?

Design Space & Documentation Requirements What is a design space? Enhanced approach - Operational ranges for one or more process parameters (forms a Design Space.) Traditional approach – Set values for process parameters.

Design Space & Documentation Requirements Traditional vs. Enhanced? …4 kg of NH 4 Cl is added to the reaction mixture… …4-5 kg of NH 4 Cl is added to the reaction mixture… …NH 4 Cl is added to the reaction mixture until a pH of 5-6 is obtained… …1-8 kg of NH 4 Cl is added to the reaction mixture… …NH 4 Cl (8 kg MAX) is added to the reaction mixture… …NH 4 Cl is added to the reaction mixture… NH 4 Cl Traditional? Enhanced?

Design Space & Documentation Requirements The manufacturer / developer possesses much more knowledge and expertise on their own manufacturing processes than any external reviewer. The intention with the documentation is to convince any external reviewer that the quality control is sufficient. The process description should be still be reproducible.

Design Space & Documentation Requirements ICH Quality Implementation Working Group: Design Space need to be clearly presented and justified in regulatory submission Design Space need to be described in sufficient details in regulatory filing Description should include critical and non critical parameters to assure complete understanding Designation of criticality need to be justified in regulatory submission based on QRM and/or experimental results

Design Space & Documentation Requirements ICH Quality Implementation Working Group: Critical parameter ranges/model are considered a regulatory commitment and non-critical parameter ranges support the review of the filing Critical parameter changes within design space are handled by the Quality System and changes outside the design space need appropriate regulatory notification Non-critical parameters would be managed by Quality System

Design Space & Documentation Requirements Identify Quality Attributes Critical Quality Attributes? Identify potentially Critical Process Parameters Experimental data and/or scientific discussion Critical Process Parameters?

Design Space & Documentation Requirements R-enantiomer Quality Attributes: S-enantiomer Potentially Critical Process parameters: Solvent ratio Temperature Critical?- Yes Acceptable limit 0.3%

Design Space & Documentation Requirements Process ParameterCritical Attribute Solvent ratioTemperatureS-enantiomer 1:320°C0.13% 3:120°C0.41% 1:360°C0.11% 3:160°C0.43% Design of Experiments at laboratoty scale (10g):

Design Space & Documentation Requirements ParametersAttribute Solvent ratioS-enantiomer 1:30.13% 1:20.18% 1:10.25% 2:10.38% Design of Experiments at laboratoty scale (10g):

Design Space & Documentation Requirements Design of Experiments at laboratoty scale (10g): Impurity Content (%) Solvent ratio

Design Space & Documentation Requirements Parameter Operational Range TargetCriticality Solvent ratio1:3 to 1:11:1Critical Process Parameter Temperature20-60°C25°C Non-Critical Process Parameter Should also be included in S.2.2 Description of Manufacturing Process

Design Space & Documentation Requirements Temperature Solvent ratio pH Second example: Design of Experiments for three process parameters S-enantiomer above 0.3% S-enantiomer below 0.3%

Design Space & Documentation Requirements Temperature Solvent ratio Second example: Design of Experiments for three process parameters Below 0.3% Above 0.3% Operational boundaries should be included in section S.2.2 and could be presented as a; figure function or range

Design Space & Documentation Requirements Full Design of Experiments on laboratory scale (10 g?) Verification on larger scale comparable to commercial scale (100 kg?) –Suitable set of experiments –Equipment comparable to that used at commercial scale –Not necessary to challange the edge of failure

Design Space & Documentation Requirements Summary of expectations from the documentation: S.2.6 Manufacturing Process Development Critical & non Critical Quality Attributes Critical & non Critical Process Parameters Based on experimental data unless justified on a rigid scientific discussion Verification on commercial scale S.2.2 Description of Manufacturing Process Criteria for process parameters clearly depicted Specified scale and expected yields

Design Space & Documentation Requirements Scope: In order to enhance the manufacturing process... Present: 10 kg of intermediate is dissolved in 100 L of water and 5 kg of reagent is added. The reaction is stirred at 50ºC for 30 minutes. The reaction mixure is extracted with 3 40 L of ethyl acetate… Proposed: The intermediate from last step is dissolved in water followed by addition of reagent (Max. 10 kg). The reaction is stirred until completion. The reaction mixure is extracted with ethyl acetate… Type IB change in the manufacturing process Wrong category Most likely not acceptable

Design Space & Documentation Requirements

?